The shares of a Microcap research-led pharmaceutical firm concerned in creating, manufacturing, and advertising and marketing generic completed dosage formulations and Oncology Formulations surged as much as 8 p.c in in the present day’s commerce after saying its growth plan into regulated markets.
Value Motion
The shares of Medicamen Biotech Ltd, with a complete market capitalization of Rs 619.52 Crore on Friday, reached an Intraday excessive at Rs 491.95 per share, gaining round 8 p.c in in the present day’s buying and selling session. As of 1:30 pm, the shares retreated from their day’s excessive and have been buying and selling at Rs 485 per share, which was 6.4 p.c increased than the earlier shut of Rs 455.9.
What occurred
In a press launch dated March 28, 2025, the corporate introduced that it has efficiently obtained approval from the European Union (EU) and america Meals and Drug Administration (USFDA) for its manufacturing vegetation, opening up important alternatives for the corporate to broaden its attain in each rising and controlled markets.
Moreover, the corporate has filed the mandatory documentation to broaden into Canada and Australia and anticipates web site approvals throughout the subsequent six months. The corporate additionally knowledgeable about partnering with worldwide companies for advertising and marketing merchandise within the US, Canada, Europe, Australia, and different rising markets.
Additionally it is centered on creating and increasing its proprietary model within the home market, specializing in high-growth therapies akin to Diabetes, Cardiovascular, and Oncology.
Indian Pharmaceutical Trade
India is among the fastest-growing and largest pharmaceutical markets globally, presenting substantial alternatives for development. Because the second fastest-growing pharma market worldwide, the Indian Pharmaceutical Market (IPM) is predicted to double from Rs 2.6 lakh crore to Rs 5.1 lakh crore by 2030. It’s projected to broaden at a compound annual development charge (CAGR) of 10.7 p.c by 2030.
Additionally learn: 1:1 Bonus Shares: Penny inventory beneath ₹10 in focus after it units file date bonus subject
Financials
The corporate reported a marginal decline of two.92 p.c YoY from Rs 46.50 Crore in Q3FY24 to Rs 45.14 Crore in Q3FY24. Nonetheless, their Web Revenue grew by 44 p.c YoY from Rs 2.03 Crore to Rs 2.92 Crore over the identical interval.
Future Outlook
The corporate is well-positioned to determine robust home manufacturers in ONCOLOGY, CVD and anti-diabetic therapies. It has chosen largest continual way of life segments and plans to broaden into extra remedy areas by 2030, with a concentrate on ortho, dermatology and gastroenterology. The corporate is aiming to have a community of over 60,000 medical doctors, and obtain a PAN India presence masking 560 HQs.
About Medicamen Biotech Ltd
Medicamen Biotech Ltd is an Indian pharmaceutical firm engaged within the manufacturing and advertising and marketing of a variety of generic medicines. It makes a speciality of high-quality formulations throughout varied therapeutic segments like Oncology, Cardio-vascular, Hypertension, and Antidiabetic.
The corporate has transitioned from a solely home authorities enterprise to a world provider by increasing its presence in ROW and rising markets. With EU and USFDA plant approvals, the corporate is now well-positioned to entry regulated markets just like the US, EU, Australia and Canada.
Written By Adhvaitha Nayani
Disclaimer
The views and funding ideas expressed by funding specialists/broking homes/ranking businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a danger of monetary losses. Buyers should subsequently train due warning whereas investing or buying and selling in shares. Dailyraven Applied sciences or the writer will not be chargeable for any losses precipitated because of the choice based mostly on this text. Please seek the advice of your funding advisor earlier than investing.
